Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email
By LabPulse.com staff writers

November 8, 2019 -- California-based genomics company DxTerity is releasing data showing the association between type 1 interferon (IFN-1) and the development of systemic lupus erythematosus on November 11 at the American College of Rheumatology (ACR) annual meeting. The data support the commercial launch of a test for the overexpression of IFN-1, the company said.

DxTerity test kit
Image courtesy of DxTerity.

Lupus is a heterogeneous disease, which has presented hurdles for conducting drug trials and developing new treatments. Consequently, biomarker development is critical. The company reported that in a longitudinal study with the Oklahoma Medical Research Foundation, there was a highly significant statistical association between type 1 interferon status and risk for developing lupus. DxTerity noted that its test is already being used in clinical trials of lupus.

Meanwhile, DxTerity is gearing up to run the direct-to-patient ELEVATE study of its modular immune profile (MIP) finger-stick blood test, which includes IFN-1 screening. The company said it aims to enroll 5,000 participants.

Progentec wins NIH grant for lupus blood tests
Progentec Diagnostics is set to receive $225,000 initially and up to $1.7 million in total through a grant from the U.S. National Institutes of Health...
Single-cell sequencing supplies clues about managing lupus
Single-cell RNA sequencing (scRNA-seq) helped researchers identify a molecular signature associated with response to treatment for lupus nephritis in...

Copyright © 2019 LabPulse.com

Last Updated np 11/7/2019 6:23:26 PM